CurrentBlue Cross Blue Shield - KansasPolicy N/A

Active versus historical malignancy documentation

Defines when a malignancy is considered active or historical for documentation and coding purposes and lists treatment types that support an active status; affects providers submitting diagnoses and claims to Blue Cross and Blue Shield of Kansas.

Policy Summary

PayerBlue Cross Blue Shield - Kansas

PolicyActive versus historical malignancy documentation

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument whether a malignancy is active or historical and include supporting treatment documentation; note hematologic exceptions and that untreated malignancy remains active.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6treatment types listed

2hematologic exceptions

1decline-treatment rule

Coverage Criteria: Active vs Historical Malignancy

Status classification

Covered when the following classification rules are met:

Active malignancy: A malignancy is considered active in the calendar years during which the initial diagnostic workup or any treatment takes place; if the patient chooses not to receive treatment, the malignancy remains active for the remainder of the patient's life.

Supported by documentation of ongoing treatments: surgery; chemotherapy; radiation; bone marrow or stem cell transplantation; hormonal or immunotherapy; adjuvant therapy (e.g., tamoxifen, anastrozole, leuprolide, bicalutamide).

Historical malignancy: Once all treatments are complete, malignancies are no longer considered active and can be documented as 'history of'.

Long-term surveillance or routine testing (e.g., PSA) to monitor for recurrence does not by itself render a historical malignancy active.

Hematologic exceptions: Certain hematological malignancies should be documented as 'in remission' after treatment is completed.

Policy Summary

PayerBlue Cross Blue Shield - Kansas

PolicyActive versus historical malignancy documentation

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionDocument whether a malignancy is active or historical and include supporting treatment documentation; note hematologic exceptions and that untreated malignancy remains active.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions and Billing Implications

Documentation Required

Required diagnostic status documentation

Providers must document malignancy diagnostic status clearly in the medical record. Indicate whether a malignancy is active or historical (or in remission for the specified hematologic exceptions). This documentation should support the ICD-10-CM diagnosis coding submitted on claims.

Required documentation: statement of active vs historical malignancy, dates of initial diagnostic workup and treatments, and description of any ongoing treatments.
If treatment is ongoing during the calendar year (initial diagnostic workup or any treatment), document as active.
When all treatments are complete and no ongoing treatment is occurring, document as history of.
Hematologic malignancy exceptions (leukemia, multiple myeloma): document as in remission after treatment is complete, per policy note.

Documentation Required

Documentation supports active malignancy coding

Document any ongoing treatments that justify an active malignancy diagnosis. Presence of these treatments in the medical record supports coding the malignancy as active for the relevant calendar year(s).

Surgery
Chemotherapy
Radiation
Bone marrow or stem cell transplantation
Hormonal or immunotherapy
Adjuvant therapy (e.g., tamoxifen, anastrozole, leuprolide, bicalutamide)
If the patient declines treatment, the malignancy remains documented as active for the remainder of the patient's life.

Definitions

inv-09: Active malignancy — definition and lifetime-active exception if patient declines treatment

DefinitionA malignancy is considered active in the calendar years during which the initial diagnostic workup or any treatment takes place.

Documentation implicationProviders must document ongoing diagnostic workup or any treatment to support active status (e.g., surgery, chemotherapy, radiation, transplant, hormonal/immunotherapy, adjuvant therapy).

inv-10: Historical malignancy — definition for when malignancy is no longer active

DefinitionOnce all treatments are complete, malignancies are no longer considered active and can be documented as 'history of'.

Surveillance noteLong-term surveillance or regular testing (e.g., PSA) to monitor for recurrence does not by itself render a historical malignancy active.

Coding/documentation implicationDocument completion of all treatments to support classification as historical rather than active.

inv-11: In remission (hematologic exceptions) — Certain hematologic malignancies should be documented as 'in remission' after treatment is completed

General ruleCertain hematological malignancies are exceptions and should be documented as 'in remission' after treatment is completed.

Listed exceptionsLeukemia (all types) — document as 'in remission' after treatment.

Listed exceptionsMultiple myeloma — document as 'in remission' after treatment.

OpenPayer

Active versus historical malignancy documentation

Coverage Criteria: Active vs Historical Malignancy

Coding Guidance

Provider Actions and Billing Implications

Background

Definitions